biostudies-literatureLiu ZNCATS NIH HHSNCI NIH HHS394-400https://www.ebi.ac.uk/biostudies/studies/S-EPMC4679504biostudies-literatureUnknown139(3)<h4>Objective</h4>Suboptimal cytoreductive surgery in advanced epithelial ovarian cancer (EOC) is associated with poor survival but it is unknown if poor outcome is due to the intrinsic biology of unresectable tumors or insufficient surgical effort resulting in residual tumor-sustaining clones. Our objective was to identify the potential molecular pathway(s) and cell type(s) that may be responsible for suboptimal surgical resection.<h4>Methods</h4>By comparing gene expression in optimally and suboptimally cytoreduced patients, we identified a gene network associated with suboptimal cytoreduction and explored the biological processes and cell types associated with this gene network.<h4>Results</h4>We show that primary tumors from suboptimally cytoreduced patients express molecular signatureGynecologic oncologySuboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation.PMC4679504R21 CA194626UL1 TR000124Agadjanian HLiu ZKarlan BYJia DAspuria PJOrsulic SBeach JAfalseSuboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation.<h4>Objective</h4>Suboptimal cytoreductive surgery in advanced epithelial ovarian cancer (EOC) is associated with poor survival but it is unknown if poor outcome is due to the intrinsic biology of unresectable tumors or insufficient surgical effort resulting in residual tumor-sustaining clones. Our objective was to identify the potential molecular pathway(s) and cell type(s) that may be responsible for suboptimal surgical resection.<h4>Methods</h4>By comparing gene expression in optimally and suboptimally cytoreduced patients, we identified a gene network associated with suboptimal cytoreduction and explored the biological processes and cell types associated with this gene network.<h4>Results</h4>We show that primary tumors from suboptimally cytoreduced patients express molecular signature2015-01-01T00:00:00Z2015 Dec2025-05-31T22:22:28.671Z2020-10-29T11:02:01ZS-EPMC46795042634831410.1016/j.ygyno.2015.08.026